文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 高等教育 > 理学 > Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
侵权投诉

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

ARTICLES

©2005 Nature Publishing Group doc.guandang.net

AntibodymediatedinvivodeliveryofsmallinterferingRNAsviacell-surfacereceptors

ErweiSong1,4,PengchengZhu1,4,Sang-KyungLee1,DipanjanChowdhury1,StevenKussman1,DerekMDykxhoorn1,YiFeng1,DeborahPalliser1,DavidBWeiner2,PremlataShankar1,WayneAMarasco3&JudyLieberman1

DeliveryofsmallinterferingRNAs(siRNAs)intocellsisakeyobstacletotheirtherapeuticapplication.Wedesigneda

protamine-antibodyfusionproteintodeliversiRNAtoHIV-infectedorenvelope-transfectedcells.Thefusionprotein(F105-P)wasdesignedwiththeprotaminecodingsequencelinkedtotheCterminusoftheheavychainFabfragmentofanHIV-1envelopeantibody.siRNAsboundtoF105-PinducedsilencingonlyincellsexpressingHIV-1envelope.Additionally,siRNAstargetedagainsttheHIV-1capsidgenegag,inhibitedHIVreplicationinhard-to-transfect,HIV-infectedprimaryTcells.

IntratumoralorintravenousinjectionofF105-P-complexedsiRNAsintomicetargetedHIVenvelope-expressingB16melanomacells,butnotnormaltissueorenvelope-negativeB16cells;injectionofF105-PwithsiRNAstargetingc-myc,MDM2andVEGFinhibitedenvelope-expressingsubcutaneousB16tumors.Furthermore,anErbB2single-chainantibodyfusedwithprotaminedeliveredsiRNAsspeci callyintoErbB2-expressingcancercells.Thisstudydemonstratesthepotentialforsystemic,cell-typespeci c,antibody-mediatedsiRNAdelivery.

ThereisincreasingenthusiasmfordevelopingtherapiesbasedonRNAinterference(RNAi)—post-transcriptionalgenesilencingmediatedbysmallRNAduplexesof19–23basepairs(bp).TheadvantageofRNAiliesinitshighspeci cityandpotentgenesilencing,coupledwiththefactthatitcanpotentiallytargeteverygeneandeverycellhasthenecessarymachinery(reviewedinref.1).Althoughsomequestionsremainaboutspeci cityandactivationofoff-targeteffects2–4,noneof

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

theseproblemshasyetbeendocumentedinvivo.Moreover,someuntowardeventscanlikelybeavoidedbyjudiciouschoiceofsequencesorchemicalmodi cationofsiRNAs.

ThemainobstacletodevelopingsiRNAasasmall-moleculedrugisdeliveringitinvivoacrossthecellmembranetothecytoplasmwhereitcanentertheRNAipathwayandguidethesequence-speci cmRNAdegradation.Intheabsenceoftransfectionreagentsorhighpressurethatmaydamagetheplasmamembrane,mostcells,includingcellsthatactivelysampletheirenvironment,suchasmacrophages,donottakeupsiRNAs.Anexceptionmaybepulmonaryepithelialcells,sinceprotectionagainstrespiratorysyncytialvirusinfectioninthelungwasachievedinonereportbynasaladministrationofsiRNAswithoutanytransfectionreagent5.EarlystudiesvalidatingthetherapeuticpotentialofsiRNAsinmiceusedhigh-pressure(so-calledhydrodynamic)intravenousinjectiontoforcesiRNAsintocells6.However,hydro-dynamicinjection,whichcausesright-sidedheartfailure,isnotpracticalforsystemichumanuse.AlthoughtransfectioncandeliversiRNAslocally,asystemicmethodtodeliversiRNAstospeci ccellsviacell-surfacereceptorswouldprovideameanstointroducesiRNAsintodesiredcellstoachievemaximaltherapeuticbene t,decreasetheamountofdrugrequiredandavoidnonspeci csilencingandtoxicityinbystandercells.

Wetookadvantageofthenucleicacid–bindingpropertiesofpro-tamine,whichnucleatesDNAinsperm,todeliversiRNAsviaananti-bodyFabfragment-protaminefusionprotein7.TheFabfragmentwasusedtoavoidpotentialsideeffectsfrominteractionsofcomplementandothermoleculeswiththeantibodyconstantregion.Asaproofofconcept,aFabantibody(F105)fragmentdirectedagainstHIV-1envelopefusedtoprotamine(F105-P)wasusedtodeliversiRNAsandsilencegeneexpressionspeci callyinHIV-infectedcellsorcellstransfectedtoexpressHIVenvelopeglycoproteingp160(HIVenv).F105-PwaspreviouslyshowntocarryplasmidDNAintoHIV-infectedcells7,8.siRNAsboundtothefusionproteinanddidnotrequirecovalentcouplingforeffectivedelivery.ThestrategywaseffectiveatdeliveringsiRNAsintoprimarycells,suchasTlymphocytes,whicharehighlyresistanttotransfection.UsingB16melanomacellstransfectedwithanexpressionvectorforHIVenv,intravenousorintratumoralinjectionofF105-P-complexedsiRNAsdeliveredsiRNAsonlyintoenv-expressing(env+)tumors,butnotintonormaltissuesorenv-negativetumors,andinhibitedtumoroutgrowthwhenthesiRNAstargetedoncogenes.Thismethodcanbegeneralizedsincewecoulduseananti-ErbB2-protaminefusionproteintodeliversiRNAsspeci callytoErbB2-expressing(ErbB2+)breastcancercells.Thisfusionprotein

InstituteforBiomedicalResearchandDepartmentofPediatrics,HarvardMedicalSchool,200LongwoodAvenue,Boston,Massachusetts02115,USA.

ofPathologyandLaboratoryMedicine,UniversityofPennsylvania,Philadelphia,Pennsylvania19104,USA.3DepartmentofCancerImmunology&AIDS,

DanaFarberCancerInstituteandDepartmentofMedicine,HarvardMedicalSchool,44BinneyStreet,Boston,Massachusetts02115,USA.4Theseauthorscontributedequallytothiswork.CorrespondenceshouldbeaddressedtoJ.L.(lieberman@cbr.med.harvard.edu).

2Department

1CBR

Publishedonline22May2005;doi:10.1038/nbt1101

NATUREBIOTECHNOLOGYVOLUME23NUMBER6JUNE2005709

第1页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email